ATE460183T1 - Viraler vektor zur verwendung in der in-vivo- gentherapie von morbus parkinson - Google Patents
Viraler vektor zur verwendung in der in-vivo- gentherapie von morbus parkinsonInfo
- Publication number
- ATE460183T1 ATE460183T1 AT04791259T AT04791259T ATE460183T1 AT E460183 T1 ATE460183 T1 AT E460183T1 AT 04791259 T AT04791259 T AT 04791259T AT 04791259 T AT04791259 T AT 04791259T AT E460183 T1 ATE460183 T1 AT E460183T1
- Authority
- AT
- Austria
- Prior art keywords
- neurturin
- gene therapy
- vivo gene
- parkinson
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200301543 | 2003-10-20 | ||
US51291803P | 2003-10-22 | 2003-10-22 | |
PCT/EP2004/052586 WO2005039643A2 (en) | 2003-10-20 | 2004-10-20 | In vivo gene therapy of parkinson's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE460183T1 true ATE460183T1 (de) | 2010-03-15 |
Family
ID=34524307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04791259T ATE460183T1 (de) | 2003-10-20 | 2004-10-20 | Viraler vektor zur verwendung in der in-vivo- gentherapie von morbus parkinson |
Country Status (14)
Country | Link |
---|---|
EP (2) | EP1677833B1 (de) |
JP (1) | JP2007509109A (de) |
KR (1) | KR20060095568A (de) |
AT (1) | ATE460183T1 (de) |
AU (1) | AU2004283053A1 (de) |
BR (1) | BRPI0415563A (de) |
CA (1) | CA2543189A1 (de) |
DE (1) | DE602004025959D1 (de) |
DK (1) | DK1677833T3 (de) |
ES (1) | ES2342397T3 (de) |
MX (1) | MXPA06004329A (de) |
NZ (1) | NZ547185A (de) |
RU (1) | RU2006117304A (de) |
WO (1) | WO2005039643A2 (de) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7276580B2 (en) | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
ES2353457T3 (es) | 2003-06-10 | 2011-03-02 | Nsgene A/S | Secreción mejorada de neublastina. |
US7598059B2 (en) | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
NZ553420A (en) | 2004-08-19 | 2010-02-26 | Biogen Idec Inc | Refolding transforming growth factor beta family proteins |
AU2006308312A1 (en) * | 2005-10-28 | 2007-05-03 | Nsgene A/S | Implantable Biocompatible Immunoisolatory Vehicle for Delivery of GDNF |
TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
US9375440B2 (en) | 2006-11-03 | 2016-06-28 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US8324367B2 (en) | 2006-11-03 | 2012-12-04 | Medtronic, Inc. | Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity |
US8329655B2 (en) | 2007-05-01 | 2012-12-11 | Biogen Idec Ma Inc. | Methods for increasing vascularization |
BRPI0819220A2 (pt) * | 2007-11-05 | 2019-02-26 | Develogen Aktiengessellschaft | proteína neurturina ou fragmento da mesma, sua composição farmacêutica e uso |
PL2307551T3 (pl) * | 2008-06-18 | 2017-07-31 | Oxford Biomedica (Uk) Limited | Oczyszczanie wektorów retrowirusowych |
AU2010313456A1 (en) * | 2009-10-30 | 2012-05-17 | Ntf Therapeutics, Inc. | Improved neurturin molecules |
RU2013129990A (ru) * | 2010-12-02 | 2015-01-10 | НЬЮРОТЕК ЮЭсЭй, ИНК. | Клеточные линии, которые секретируют конструкции "антиангиогенное антитело-каркасы" и растворимые рецепторы, и их применение |
DK2661494T3 (da) * | 2011-01-07 | 2019-09-02 | Applied Genetic Tech Corporation | Promotorer, ekspressionskassetter og vektorer til anvendelse ved behandling af achromatopsi og andre sygdomme |
CA2878401C (en) * | 2012-07-06 | 2022-07-19 | University Of Iowa Research Foundation | Modified adeno-associated virus vector compositions |
JP6320382B2 (ja) | 2012-08-13 | 2018-05-09 | ザ ロックフェラー ユニヴァーシティ | メラノーマの処置および診断 |
CA2890045C (en) | 2012-10-31 | 2016-11-15 | The Rockefeller University | Treatment and diagnosis of colon cancer |
CN103981147B (zh) | 2013-02-08 | 2017-11-10 | 中国科学院上海生命科学研究院 | 一种新的制备肝实质细胞的方法 |
EP3292206B8 (de) | 2015-05-07 | 2022-02-09 | Takeda Pharmaceutical Company Limited | Glucocerebrosidase gentherapie von morbus parkinson |
US10016514B2 (en) | 2015-05-15 | 2018-07-10 | New Hope Research Foundation | Polynucleotides, vectors and methods for insertion and expression of transgenes |
EP3374504A2 (de) * | 2015-11-09 | 2018-09-19 | CureVac AG | Optimierte nukleinsäuremoleküle |
JP2021504315A (ja) | 2017-11-21 | 2021-02-15 | ルジェニクス,インコーポレーテッド | 多形及びその使用 |
US11174220B2 (en) | 2019-12-13 | 2021-11-16 | Inspirna, Inc. | Metal salts and uses thereof |
WO2024091824A1 (en) | 2022-10-26 | 2024-05-02 | Ada Forsyth Institute, Inc. | Differentiation and reprogramming of chondrocyte |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE68013T1 (de) | 1985-07-05 | 1991-10-15 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
DE3852823T2 (de) | 1987-09-11 | 1995-05-24 | Whitehead Biomedical Inst | Transduktionsveränderte fibroblasten und ihre anwendung. |
US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US5487739A (en) | 1987-11-17 | 1996-01-30 | Brown University Research Foundation | Implantable therapy systems and methods |
US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
US5156844A (en) | 1987-11-17 | 1992-10-20 | Brown University Research Foundation | Neurological therapy system |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
DE3829766A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Verfahren zur herstellung von membranen |
DE3829752A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
EP0585368B1 (de) | 1991-04-25 | 1997-08-06 | Brown University Research Foundation | Implantierbare, biokompatible immunisolator-trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte |
US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
CA2166116A1 (en) | 1993-06-23 | 1995-01-12 | John F. Mills | Method and apparatus for sealing implantable, membrane encapsulation devices |
DK0802800T3 (da) | 1993-08-12 | 2002-10-07 | Neurotech Sa | Biokompatible immunoisolatoriske kapsler indeholdende genetisk ændrede celler for levering af biologisk aktive molekyler |
WO1995024929A2 (en) | 1994-03-15 | 1995-09-21 | Brown University Research Foundation | Polymeric gene delivery system |
US20020031493A1 (en) | 1994-03-25 | 2002-03-14 | Rhone-Poulenc Rorer S.A. | Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf) |
ATE386131T1 (de) | 1994-04-13 | 2008-03-15 | Univ Rockefeller | Aav-vermittelte überbringung von dna in zellen des nervensystems |
US5550050A (en) | 1994-04-15 | 1996-08-27 | Cytotherapeutics, Inc. | Method for implanting encapsulated cells in a host |
US5656465A (en) | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
US5677158A (en) | 1995-06-07 | 1997-10-14 | Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
US5739307A (en) | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
US6184200B1 (en) | 1995-09-28 | 2001-02-06 | Amgen Inc. | Truncated glial cell line-derived neurotrophic factor |
US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
US5904144A (en) | 1996-03-22 | 1999-05-18 | Cytotherapeutics, Inc. | Method for treating ophthalmic diseases |
US6027721A (en) * | 1996-05-20 | 2000-02-22 | Cytotherapeutics, Inc. | Device and method for encapsulated gene therapy |
US6054142A (en) | 1996-08-01 | 2000-04-25 | Cyto Therapeutics, Inc. | Biocompatible devices with foam scaffolds |
EP1304119A3 (de) * | 1997-07-30 | 2004-01-21 | Amgen Inc. | Verfahren zur Vorbeugung und Behandlung von Gehörverlust mit Neurturin Protein |
US6136597A (en) | 1997-09-18 | 2000-10-24 | The Salk Institute For Biological Studies | RNA export element |
US6303136B1 (en) | 1998-04-13 | 2001-10-16 | Neurotech S.A. | Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane |
US6451306B1 (en) | 1998-04-15 | 2002-09-17 | The Regents Of The University Of California | Methods for therapy of neurodegenerative disease of the brain |
DE69941100D1 (de) | 1998-05-27 | 2009-08-20 | Genzyme Corp | AAV Vektoren zur Herstellung der Medikamente zur konvektion-erhöhten Verabreichung |
US20020055467A1 (en) | 1998-07-06 | 2002-05-09 | Johansen Teit E. | Novel neurotrophic factors |
US6361741B1 (en) | 1999-02-01 | 2002-03-26 | Alcoa Inc. | Brazeable 6XXX alloy with B-rated or better machinability |
US6361771B1 (en) | 1999-04-06 | 2002-03-26 | Neurotech S.A. | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
US20020037281A1 (en) | 2000-05-26 | 2002-03-28 | Davidson Beverly L. | Methods of transducing neural cells using lentivirus vectors |
US6555674B2 (en) | 2000-08-09 | 2003-04-29 | Nsgene A/S | JeT promoter |
US6800281B2 (en) | 2000-11-09 | 2004-10-05 | Oxford Biomedica (Uk) Limited | Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases |
US20030050273A1 (en) | 2001-08-29 | 2003-03-13 | Keiya Ozawa | Compositions and methods for treating neurodegenerative diseases |
-
2004
- 2004-10-20 JP JP2006536086A patent/JP2007509109A/ja not_active Withdrawn
- 2004-10-20 EP EP04791259A patent/EP1677833B1/de not_active Not-in-force
- 2004-10-20 KR KR1020067007666A patent/KR20060095568A/ko not_active Application Discontinuation
- 2004-10-20 AT AT04791259T patent/ATE460183T1/de not_active IP Right Cessation
- 2004-10-20 NZ NZ547185A patent/NZ547185A/en not_active IP Right Cessation
- 2004-10-20 CA CA002543189A patent/CA2543189A1/en not_active Abandoned
- 2004-10-20 RU RU2006117304/15A patent/RU2006117304A/ru unknown
- 2004-10-20 WO PCT/EP2004/052586 patent/WO2005039643A2/en active Application Filing
- 2004-10-20 BR BRPI0415563-7A patent/BRPI0415563A/pt not_active Application Discontinuation
- 2004-10-20 DE DE602004025959T patent/DE602004025959D1/de active Active
- 2004-10-20 EP EP10155955A patent/EP2210617A1/de not_active Withdrawn
- 2004-10-20 ES ES04791259T patent/ES2342397T3/es active Active
- 2004-10-20 AU AU2004283053A patent/AU2004283053A1/en not_active Abandoned
- 2004-10-20 DK DK04791259.7T patent/DK1677833T3/da active
- 2004-10-20 MX MXPA06004329A patent/MXPA06004329A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20060095568A (ko) | 2006-08-31 |
MXPA06004329A (es) | 2006-06-05 |
WO2005039643A3 (en) | 2005-11-17 |
BRPI0415563A (pt) | 2007-01-02 |
JP2007509109A (ja) | 2007-04-12 |
RU2006117304A (ru) | 2007-12-10 |
CA2543189A1 (en) | 2005-05-06 |
EP1677833B1 (de) | 2010-03-10 |
EP2210617A1 (de) | 2010-07-28 |
DE602004025959D1 (de) | 2010-04-22 |
NZ547185A (en) | 2009-03-31 |
DK1677833T3 (da) | 2010-05-17 |
ES2342397T3 (es) | 2010-07-06 |
AU2004283053A1 (en) | 2005-05-06 |
EP1677833A2 (de) | 2006-07-12 |
WO2005039643A2 (en) | 2005-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE460183T1 (de) | Viraler vektor zur verwendung in der in-vivo- gentherapie von morbus parkinson | |
WO1998049300A3 (en) | Truncated vegf-related proteins | |
BE2014C077I2 (de) | ||
WO2003104270A3 (en) | GENES OF DUDULINE 2, EXPRESSION PRODUCTS, NON-HUMAN ANIMAL MODEL: USES IN HUMAN HEMATOLOGICAL DISEASES | |
BR0207110A (pt) | Pró-peptìdeos de gdf modificados e estabilizados e usos dos mesmos | |
EA200800368A1 (ru) | Гликозилированный il-7, получение и применение | |
ATE430763T1 (de) | Therapeutische verwendung des wachstumsfaktors nsg33 | |
EP1315965A4 (de) | Verfahren und zusammensetzungen für "targeting" in vitro | |
IL141141A0 (en) | Targeting pharmaceutical agents to injured tissues | |
WO2003024502A3 (en) | Compositions and methods useful for non-invasive delivery of therapeutic molecules to the bloodstream | |
IL142989A0 (en) | Nucleotide and protein sequences of nogo genes and methods based thereon | |
ATE457359T1 (de) | Auf lps-reagierendes chs1/beige-ähnliches anker- gen und therapeutische anwendungen davon | |
MXPA04003944A (es) | Una composicion y metodo para alterar la masa corporal fina y propiedades oseas en un sujeto. | |
AU2003239823A8 (en) | Optimization of transgene expression in mammalian cells | |
EP1209226A3 (de) | Reifen von dendritischen Zellen durch die Verwendung von rekombinante Hitzeschock-Protein 70 (hsp70) | |
CN116115831B (zh) | 一种具有生物活性的可透皮光固化成形水凝胶及其制备方法与应用 | |
EP4067374A1 (de) | Fgf2-polypeptid mit verbesserter temperaturstabilität und proteaseresistenz und seine verwendung | |
RU2007124538A (ru) | Фармацевтическая композиция для генной терапии заболеваний, требующих стимуляции регенераторных процессов, включая повреждения тканей человека различной этиологии, на основе синтетического модифицированного гена инсулиноподобного фактора роста человека первого типа (ифр-1, igf-1) | |
WO2005084691B1 (en) | Method of proliferating precursor cells | |
ATE529438T1 (de) | Dna-sequenz und rekombinante herstellung des graspollen-allergens lol p 4 | |
EP1090995A3 (de) | Mycoplasma hyopneumoniae Antigen MHP3, dafür kodierendes Gen und Ihre Verwendungen | |
WO2006072601A3 (en) | THERAPEUTIC USE OF GROWTH FACTORS, NsG29 AND NsG31 | |
ATE394420T1 (de) | Gen in zusammenhang mit haarausfall, das davon kodierte polypeptid und anwendungen dafür | |
EP1679372A4 (de) | Neues plexin-polypeptid, dieses codierende dna und verwendung davon | |
WO2001075046A3 (fr) | Nouveau polypeptide, gene humain de regulation 17 du cycle mitotique, et polynucleotide codant pour ce polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |